%0 Journal Article %T KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer %A Horinouchi, Hidehito %J Journal of Thoracic Disease %D 2017 %B 2017 %9 %! KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer %K %X The KEYNOTE 021 trial was a randomized phase II/III trial comparing docetaxel and pembrolizumab as a secondline treatment for non-small cell lung cancer (NSCLC) in which 202 institutions from 24 countries participated (1). Eligible patients were as follows: progression after treatment with platinum combination therapy, EGFRTKI or AKL-TKI; an age of 18 years or older; an Eastern Cooperative Oncology Group Performance Status (ECOGPS) of 0/1; and programmed death-ligand 1 (PD-L1) with a tumor proportion score (TPS) of 1% or more. %U https://jtd.amegroups.org/article/view/16904 %V 9 %N 11 %P 4187-4190 %@ 2077-6624